903899-13-8 | Pyridine-derivatives

Wolkenberg, Scott E.’s team published research in Journal of Medicinal Chemistry in 54 | CAS: 903899-13-8

Journal of Medicinal Chemistry published new progress about 903899-13-8. 903899-13-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Alcohol,Boronic Acids,Boronic acid and ester, name is (6-Hydroxypyridin-3-yl)boronic acid, and the molecular formula is C3H5BN2O2, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid.

Wolkenberg, Scott E. published the artcileDesign, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid, the publication is Journal of Medicinal Chemistry (2011), 54(7), 2351-2358, database is CAplus and MEDLINE.

Agonists of somatostatin receptor subtype 2 (sst₂) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst₂, and these were optimized to provide small mols. with sst₂ binding and functional potency comparable to peptide agonists. Agonist I was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Hu, Yonghan’s team published research in Bioorganic & Medicinal Chemistry Letters in 21 | CAS: 903899-13-8

Bioorganic & Medicinal Chemistry Letters published new progress about 903899-13-8. 903899-13-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Alcohol,Boronic Acids,Boronic acid and ester, name is (6-Hydroxypyridin-3-yl)boronic acid, and the molecular formula is C5H6BNO3, SDS of cas: 903899-13-8.

Hu, Yonghan published the artcileContinued exploration of biphenylsulfonamide scaffold as a platform for aggrecanase-1 inhibition, SDS of cas: 903899-13-8, the publication is Bioorganic & Medicinal Chemistry Letters (2011), 21(22), 6800-6803, database is CAplus and MEDLINE.

Design, synthesis and structure-activity relationship of a series of biphenylsulfonamido-3-methylbutanoic acid based aggrecanase-1 inhibitors are described. In addition to robust aggrecanase-1 inhibition, these compounds also exhibit potent MMP-13 activity. In cell-based cartilage explants assay 4-[4-(3-F₃CC₆H₄)C₆H₄]C₆H₄SO₂NH-L-Val-OH produced 87% inhibition of proteoglycan degradation at 10 μg/mL. Good pharmacokinetic properties were demonstrated by 4-[4-(2-NCC₆H₄)C₆H₄]C₆H₄SO₂NH-L-Val-OH with a half-life of 6 h and bioavailability of 23%.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Wolkenberg, Scott E.’s team published research in Journal of Medicinal Chemistry in 54 | CAS: 903899-13-8

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Hu, Yonghan’s team published research in Bioorganic & Medicinal Chemistry Letters in 21 | CAS: 903899-13-8

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Owen, Dafydd R.’s team published research in Bioorganic & Medicinal Chemistry Letters in 19 | CAS: 903899-13-8

Owen, Dafydd R. published the artcileIdentification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors, Application of (6-Hydroxypyridin-3-yl)boronic acid, the publication is Bioorganic & Medicinal Chemistry Letters (2009), 19(15), 4088-4091, database is CAplus and MEDLINE.

A new class of potent and selective PDE5 inhibitors is disclosed. Guided by X-ray crystallog. data, optimization of an HTS lead led to the discovery of a series of 2-aryl-8-alkyl-6-aminopyrido[3,2b]pyrazinones which show potent inhibition of the PDE5 enzyme. Synthetic details and some structure-activity relationships are also presented.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Oi, Norihito’s team published research in Journal of Medicinal Chemistry in 58 | CAS: 903899-13-8

Oi, Norihito published the artcileDevelopment of Novel PET Probes for Central 2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid Receptors, SDS of cas: 903899-13-8, the publication is Journal of Medicinal Chemistry (2015), 58(21), 8444-8462, database is CAplus and MEDLINE.

The authors document the development of PET probes for central AMPA receptors and their application to in vivo animal imaging. An initial screening of perampanel derivatives was performed to identify probe candidates. Despite the high autoradiog. contrast yielded by several radioligands, rat PET scans did not support their in vivo suitability. Further focused derivatization and a second screening by ex vivo LC-MS measurements led to the selection of 2-[1-(3-methylaminophenyl)-2-oxo-5-(pyrimidin-2-yl)-1,2-dihydropyridin-3-yl]benzonitrile, 21a, and its analogs as candidates. [¹¹C]21a was shown by autoradiog. to specifically bind to the neocortex and hippocampus, consistent with AMPA receptor localization. PET imaging with [¹¹C]21a demonstrated moderate uptake of radioactivity in rat and monkey brains, with the retention of radiosignals being consistent with that from the autoradiogram data, and the uptake was blocked by pretreatment with unlabeled 21a in a dose-dependent manner. The current approach has facilitated the discovery of a PET probe potentially suitable for translational research and development focused on AMPA receptors.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Patel, Paresma R.’s team published research in Bioorganic & Medicinal Chemistry Letters in 26 | CAS: 903899-13-8

Patel, Paresma R. published the artcileIn vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents, Synthetic Route of 903899-13-8, the publication is Bioorganic & Medicinal Chemistry Letters (2016), 26(12), 2907-2911, database is CAplus and MEDLINE.

Novel imidazo[4,5-c]quinolin-2-ones, such as I, were synthesized and evaluated in asexual blood stage and late stage gametocyte assays of Plasmodium falciparum, a major causative agent of malaria. The design of these compounds is based on a recently identified lead compound from a high throughput screen. A concise synthesis was developed that allowed for generation of analogs with substitution around both the quinoline and imidazolidinone rings. Through structure-activity relationship studies, a number of potent compounds were identified that possessed excellent antimalarial activity against both the asexual and sexual stages with minimal cytotoxicity in mammalian cells. This is the first Letter describing SAR and gametocytocidal activity of imidazo[4,5-c]quinolin-2-ones, a new lead series for malaria treatment and prevention.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Li, Hao’s team published research in ACS Combinatorial Science in 19 | CAS: 903899-13-8

ACS Combinatorial Science published new progress about 903899-13-8. 903899-13-8 belongs to pyridine-derivatives, auxiliary class Pyridine,Boronic acid and ester,Alcohol,Boronic Acids,Boronic acid and ester, name is (6-Hydroxypyridin-3-yl)boronic acid, and the molecular formula is C5H6BNO3, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid.

Li, Hao published the artcileEfficient Synthesis of 1,9-Substituted Benzo[h][1,6]naphthyridin-2(1H)-ones and Evaluation of their Plasmodium falciparum Gametocytocidal Activities, Recommanded Product: (6-Hydroxypyridin-3-yl)boronic acid, the publication is ACS Combinatorial Science (2017), 19(12), 748-754, database is CAplus and MEDLINE.

A novel three-component, two-step, 1-pot nucleophilic aromatic substitution (S_NAr)-intramol. cyclization-Suzuki coupling reaction was developed for the synthesis of benzo[h][1,6]naphthyridin-2(1H)-ones (Torins). On the basis of the new efficiently convergent synthetic route, a library of Torin 2 analogs was synthesized. The antimalarial activities of these compounds were evaluated against asexual parasites using a growth inhibition assay and gametocytes using a viability assay.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Hendricks, Robert T.’s team published research in Bioorganic & Medicinal Chemistry Letters in 19 | CAS: 903899-13-8

Hendricks, Robert T. published the artcile3-Hydroxyisoquinolines as inhibitors of HCV NS5b RNA-dependent RNA polymerase, SDS of cas: 903899-13-8, the publication is Bioorganic & Medicinal Chemistry Letters (2009), 19(2), 410-414, database is CAplus and MEDLINE.

Isoquinoline-based non-nucleoside inhibitors of HCV NS5b RNA-dependent RNA-polymerase are described. The synthesis and structure-activity relationships are detailed, along with enzyme and cellular activity.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Verheijen, Jeroen C.’s team published research in Journal of Medicinal Chemistry in 52 | CAS: 903899-13-8

Verheijen, Jeroen C. published the artcileDiscovery of 4-Morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the 6-Aryl Substituent, Name: (6-Hydroxypyridin-3-yl)boronic acid, the publication is Journal of Medicinal Chemistry (2009), 52(24), 8010-8024, database is CAplus and MEDLINE.

Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines, e.g. I, as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase α (PI3K-α), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC₅₀ against mTOR and greater than 1000-fold selectivity over PI3K-α. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC₅₀ < 1 nM) with unprecedented activity in cellular proliferation assays (IC₅₀ < 1 nM).

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem